表紙
市場調查報告書

生物學性治療藥的全球市場:2018年∼2022年

Global Biologic Therapeutics Market 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 317801
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
生物學性治療藥的全球市場:2018年∼2022年 Global Biologic Therapeutics Market 2018-2022
出版日期: 2018年12月19日內容資訊: 英文 120 Pages
簡介

全球生物學性治療藥市場到2022年前,預測將以超越11%的年複合成長率擴大。

本報告提供全球生物學性治療藥市場相關調查分析,提供市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 本報告的調查範圍

第3章 調查手法

第4章 市場形勢

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第5章 開發平台分析

第6章 市場規模

  • 市場定義
  • 市場規模
  • 市場規模與預測

第7章 波特的五力分析

第8章 治療藥類別的市場分類

  • 分類
  • 比較
  • 單株抗體 - 市場規模與預測
  • 其他 - 市場規模與預測
  • 疫苗 - 市場規模與預測
  • 細胞及組織療法 - 市場規模與預測
  • 遺傳基因療法 - 市場規模與預測
  • 市場機會

第9章 各用途的市場分類

  • 腫瘤
  • 自體免疫疾病及發炎性疾病
  • 血液疾病
  • 其他

第10章 客戶形勢

第11章 地區形勢

  • 地理區分
  • 地區比較
  • 南北美洲 - 市場規模與預測
  • 歐洲·中東·非洲地區 - 市場規模與預測
  • 亞太地區 - 市場規模與預測
  • 市場機會

第12章 決策架構

第13章 市場成長因素與課題

  • 市場成長因素
  • 市場課題

第14章 市場趨勢

第15章 業者情勢

  • 概要
  • 創造性破壞狀況

第16章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • AbbVie
  • Johnson & Johnson
  • Merck
  • Pfizer

第17章 附錄

  • 簡稱清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR21669

About this market

Increasing incidence of chronic diseases and immunological disorders to drive growth in the market. Biologics are ideal for the treatment of chronic disorders including cancer, autoimmune disorders, hormonal deficiencies, neurological disorders, and other critical conditions. The incidence of these diseases is rising significantly in developed nations. The increase in aging population and the lifestyle of people in these countries is responsible for the rise in occurrence of cancer, immunological disorders, and other chronic ailments. Technavio' s analysts have predicted that the biologic therapeutics market will register a CAGR of over11% by 2022.

Market Overview

Increasing investment in development of biologics

Biotechnological products help manufacturers to earn huge revenues because of the therapeutic benefits they provide. Thus, many pharmaceutical companies are moving toward the development of biologics.

Reimbursement challenges of new biologics

The reimbursements available for biologics are very limited compared with that available for conventional therapeutics, despite the high costs. Manufacturers are providing biologics with mandatory companion diagnostics, which increases the overall cost of that biologic, making it difficult for insurers to provide reimbursements.

For the detailed list of factors that will drive and challenge the growth of the biologic therapeutics market during the 2018-2022, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Merck and Pfizer the competitive environment is quite intense. Factors such as the increasing incidence of chronic diseases and immunological disorders and the increasing investment in development of biologics, will provide considerable growth opportunities to biologic therapeutics manufactures. AbbVie, Johnson & Johnson, Merck, and Pfizer are some of the major companies covered in this report.

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY TYPE OF THERAPEUTIC AGENT

  • Segmentation by therapeutic agent
  • Comparison by therapeutic agent
  • Monoclonal antibodies - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Vaccines - Market size and forecast 2017-2022
  • Cell and tissue-based therapy - Market size and forecast 2017-2022
  • Gene therapy - Market size and forecast 2017-2022
  • Market opportunity by therapeutic agent

PART 09: MARKET SEGMENTATION BY APPLICATION

  • Oncology
  • Autoimmune and inflammatory diseases
  • Hematology
  • Others

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • Johnson & Johnson
  • Merck
  • Pfizer

PART 17: APPENDIX

  • List of abbreviations
  • Exhibit 01: Parent market
  • Exhibit 02: Global biologic therapeutics market: Segmentation
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Biologics in pipeline 2017-2018
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2017
  • Exhibit 19: Global biologic therapeutics market - Market share by therapeutic agent 2017-2022 (%)
  • Exhibit 20: Comparison by therapeutic agent
  • Exhibit 21: Monoclonal antibodies - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 22: Sales of major monoclonal antibodies 2015-2017
  • Exhibit 23: Monoclonal antibodies - Year-over-year growth 2018-2022 (%)
  • Exhibit 24: Others - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 25: Others - Year-over-year growth 2018-2022 (%)
  • Exhibit 26: Vaccines - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 27: Vaccines - Year-over-year growth 2018-2022 (%)
  • Exhibit 28: Cell and tissue-based therapy - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 29: Cell and tissue-based therapy - Year-over-year growth 2018-2022 (%)
  • Exhibit 30: Gene therapy- Market size and forecast 2017-2022 ($ bn)
  • Exhibit 31: Gene therapy- Year-over-year growth 2018-2022 (%)
  • Exhibit 32: Market opportunity by type of therapeutic agent
  • Exhibit 33: Sales of biologics used in oncology 2015-2017 ($ millions)
  • Exhibit 34: Customer landscape
  • Exhibit 35: Global biologic therapeutics market - Market share by geography 2017-2022 (%)
  • Exhibit 36: Regional comparison
  • Exhibit 37: Americas - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 38: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 39: Top three countries in Americas
  • Exhibit 40: EMEA - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 41: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 42: Top three countries in EMEA
  • Exhibit 43: APAC - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 44: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 45: Top three countries in APAC
  • Exhibit 46: Market opportunity
  • Exhibit 47: Treatment costs of some recently approved biologics in US
  • Exhibit 48: Patent expiration dates of some biologics
  • Exhibit 49: Vendor landscape
  • Exhibit 50: Landscape disruption
  • Exhibit 51: Vendor classification
  • Exhibit 52: Market positioning of vendors
  • Exhibit 53: AbbVie overview
  • Exhibit 54: AbbVie - Business segments
  • Exhibit 55: AbbVie - Organizational developments
  • Exhibit 56: AbbVie - Geographic focus
  • Exhibit 57: AbbVie - Key offerings
  • Exhibit 58: Johnson & Johnson overview
  • Exhibit 59: Johnson & Johnson - Business segments
  • Exhibit 60: Johnson & Johnson - Organizational developments
  • Exhibit 61: Johnson & Johnson Geographic focus
  • Exhibit 62: Johnson & Johnson - Segment focus
  • Exhibit 63: Johnson & Johnson - Key offerings
  • Exhibit 64: Merck overview
  • Exhibit 65: Merck - Business segments
  • Exhibit 66: Merck - Organizational developments
  • Exhibit 67: Merck - Geographic focus
  • Exhibit 68: Merck - Segment focus
  • Exhibit 69: Merck - Key offerings
  • Exhibit 70: Pfizer overview
  • Exhibit 71: Pfizer - Business segments
  • Exhibit 72: Pfizer - Organizational developments
  • Exhibit 73: Pfizer - Geographic focus
  • Exhibit 74: Pfizer - Segment focus
  • Exhibit 75: Pfizer - Key offerings
Back to Top